Vanguard Group Inc Harrow Health, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Harrow Health, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,829,805 shares of HROW stock, worth $39.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,829,805

Previous 1,808,552 1.18%

Holding current value

$39.6 Million

Previous $20.3 Million 19.52%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$9.3 - $13.23 $197,652 - $281,177	21,253 Added 1.18%	1,829,805 $24.2 Million
Q4 2023 Feb 14, 2024	BUY	$8.1 - $16.36 $394,251 - $796,290	48,673 Added 2.77%	1,808,552 $20.3 Million
Q3 2023 Nov 14, 2023	BUY	$14.03 - $22.08 $1.34 Million - $2.11 Million	95,389 Added 5.73%	1,759,879 $25.3 Million
Q2 2023 Aug 14, 2023	BUY	$17.37 - $28.08 $4.83 Million - $7.81 Million	278,164 Added 20.06%	1,664,490 $31.7 Million
Q1 2023 May 15, 2023	BUY	$13.84 - $21.46 $2.96 Million - $4.58 Million	213,530 Added 18.21%	1,386,326 $29.3 Million

Q4 2022 Feb 10, 2023	SELL	$10.28 - $14.78 $80,286 - $115,431	-7,810 Reduced 0.66%	1,172,796 $17.3 Million
Q2 2022 Aug 12, 2022	BUY	$5.75 - $7.74 $589,518 - $793,543	102,525 Added 9.51%	1,180,606 $8.59 Million
Q1 2022 May 13, 2022	SELL	$6.77 - $8.66 $47,241 - $60,429	-6,978 Reduced 0.64%	1,078,081 $7.35 Million
Q4 2021 Feb 14, 2022	SELL	$8.5 - $12.0 $12,537 - $17,700	-1,475 Reduced 0.14%	1,085,059 $9.38 Million
Q2 2021 Aug 13, 2021	BUY	$6.68 - $11.07 $7.26 Million - $12 Million	1,086,534 New	1,086,534 $10.1 Million

Others Institutions Holding HROW

# of Institutions

123

Shares Held

21.3M

Call Options Held

113K

Put Options Held

366K

View Full List

About HARROW HEALTH, INC.

Ticker HROW
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 27,070,000
Market Cap $586M
Description
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company tha...

More about HROW

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Harrow Health, Inc. Transaction History